

**61<sup>ST</sup>** ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*



# INDUSTRY SYMPOSIA BOOKLET

**23  
MAY**

## INDUSTRY SYMPOSIA BOOKLET

**THURSDAY, MAY 23: 12:15 – 13:15**

**61<sup>ST</sup> ERA  
CONGRESS**  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE	
A4	CSL Vifor	0.1	Symptom-orientated care in dialysis: a spotlight on CKD-associated Pruritus	
A5	GSK Ltd	0.2	KDIGO update: The impact of viral infections in patients with renal diseases and the role of vaccination in kidney care	
A6	AstraZeneca	0.3	Carrying the torch: SGLT2 inhibitors as a standard of care for CKD	



**24  
MAY**

## INDUSTRY SYMPOSIA BOOKLET

**FRIDAY, MAY 24: 10:15 – 11:15**

**61<sup>ST</sup> ERA  
CONGRESS**  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE	
K1+K2	GlaxoSmithKline	1.1	Advancing lupus nephritis care: acting early to preserve the kidney	
A2+A3	Boehringer Ingelheim International GmbH	1.2	Slope of change in the right direction: overcoming residual risk for progression in CKD	
A4	Sobi	1.3	Time for change: A new era for C3G and primary IC-MPGN	
A5	CSL Vifor	1.4	Chronic cardiovascular–kidney disorder – optimizing therapy through a multidisciplinary approach	
A6	Med Learning Group	1.5	Comprehensive Approaches to Chronic Kidney Disease: Improving Diagnosis and Patient Management	
A7	STADA AG	1.6	Addressing the “IgA” in IgAN	
T5	Science Collected	1.7	Our call to action: A united approach to managing hyperkalaemia in patients with cardiorenal disease	

3



This Symposium is restricted to Healthcare professionals only.

**24  
MAY**

## INDUSTRY SYMPOSIA BOOKLET

**61<sup>ST</sup> ERA  
CONGRESS**  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

**FRIDAY, MAY 24: 13:45 – 14:45**

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE
K1+K2	Vera Therapeutics	1.8	Targeting the Source of IgA Nephropathy: Focus on BAFF and APRIL Pathways.
A2+A3	Fresenius Medical Care Deutschland GmbH	1.9	Is high-volume HDF the future standard of care in chronic dialysis?
A4	Novartis Pharma AG	1.10	Should disease control be redefined in C3G? Current evidence targeting the alternative complement pathway as the underlying cause of C3G 
A5	Medelligence, Inc.	1.11	Elevating AAV Care: Expert Strategies for Optimal Patient Outcomes
A6	KDIGO (Kidney Disease: Improving Global Outcomes)	1.12	KDIGO 2024 Guideline for Lupus Nephritis - A Roundtable Discussion
A7	AstraZeneca	1.13	Staying INFORMed: Preparing for the future of SARS-CoV-2 in patients with chronic kidney disease 
T5	Sanofi	1.14	Fabry First: Monitoring Matters 

**FRIDAY, MAY 24: 18:15 – 19:15**

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE
A4	Eurofins Biomnis – Eurofins Transplant Diagnostics	1.15	Genetics for kidney diseases: from nephropathies diagnosis to transplant management
A5	Alexion, AstraZeneca Rare Disease	1.16	Challenges in the personalized management of atypical haemolytic uraemic syndrome (aHUS)
A6	Jafron Biomedical Co., Ltd.	1.17	Hemoabsorption for Kidney Health

 This Symposium is restricted to Healthcare professionals only.

**25  
MAY**

## INDUSTRY SYMPOSIA BOOKLET

**61<sup>ST</sup> ERA  
CONGRESS**  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

**SATURDAY, MAY 25: 10:15 – 11:15**

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE
K1+K2	Asahi Kasei Medical Europe GmbH	2.1	Therapeutic apheresis: efficacy at cellular levels
A2+A3	Calliditas Therapeutics	2.2	Clinical markers in IgA nephropathy: Is all proteinuria the same?
A4	The Boehringer Ingelheim and Eli Lilly and Company Alliance	2.3	Making a difference with SGLT2 inhibitors in cardiovascular, renal and metabolic conditions: what has clinical experience taught us?
A5	Zydus Lifesciences Limited	2.4	Evolving Strategies in the Management of Anemia in CKD & ESRD - Focus on HIF-PHIs 
A6	Astellas Pharma Inc.	2.5	Anaemia of CKD: towards long-term treatment success 
A7	Nipro Medical Europe	2.6	Individualization in dialysis: elevating quality of life. New practical approach or just wishful thinking? 
T5	Otsuka Pharmaceutical Europe Ltd.	2.7	What's new in Lupus Nephritis: from guidelines to real-world practices 

5



This Symposium is restricted to Healthcare professionals only.

**25  
MAY**

## INDUSTRY SYMPOSIA BOOKLET

**SATURDAY, MAY 25: 13:45 – 14:45**

**61<sup>ST</sup> ERA  
CONGRESS**  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

ROOM	COMPANY NAME	ISS NUMBER	SESSION TITLE
K1+K2	Novo Nordisk A/S	2.8	GLP-1 RAs: new possibilities for managing CKD in people with obesity and type 2 diabetes
A2+A3	Medtelligence, Inc.	2.9	Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes
A4	Medscape Education Global	2.10	A New Era in Transforming Kidney Health: A Case-Based Showdown Between Audience and Experts 
A5	Novartis Pharma AG	2.11	A New Era for Managing IgA Nephropathy: Evolution of Clinical Approaches 
A6	Bayer AG	2.12	Finerenone in Practice – Bridging evidence and guidelines with clinical use 
A7	Chiesi Farmaceutici SpA	2.13	Nephrologists as Decision-Makers: holistic approach for a pioneering Care in Rare Genetic Disorders 
T5	MEDICE Arzneimittel Pütter GmbH & Co KG	2.14	The changing landscape of anaemia management in dialysis patients. 

6



This Symposium is restricted to Healthcare professionals only.

# SYMPTOM-ORIENTATED CARE IN DIALYSIS: A SPOTLIGHT ON CKD-ASSOCIATED PRURITUS

Thursday 23 May 2024, 12.15–13.15 CEST

Room A4, Stockholmsmässan, Sweden

Dear Colleague,

It is my pleasure to invite you to this CSL Vifor-sponsored educational symposium entitled '**Symptom-oriented care in dialysis: a spotlight on CKD-associated Pruritus**'.

People with CKD on haemodialysis experience a high symptom burden that can severely impact quality of life (QoL) and mental well-being. Therefore, it is essential that these symptoms and their impact on patients are appreciated, and that a comprehensive strategy for symptom management is implemented. In this symposium, we will discuss the symptom burden experienced by patients and the importance of the patient's perspective in symptom management. We will also explore the critical role played by nurses in symptom screening in dialysis clinics and highlight how symptom-oriented care can best be applied. Finally, this session will include a discussion on the use of patient-reported outcome measures (PROMs) in routine dialysis care and how these can improve patients' QoL.

CKD-associated Pruritus is an important yet under-reported symptom that can have a significant negative impact on patients. The expert speakers will provide an overview of the pathogenesis, diagnosis and prevalence of CKD-associated Pruritus, before sharing hands-on experience of its real-world management. The symposium will conclude with a live Q&A session with the expert faculty, giving an opportunity for audience questions to be discussed.

We eagerly await your participation in this engaging and educational symposium.



Professor Stefan Jacobson  
Chair

## PROGRAMME

### Welcome

Stefan Jacobson, Sweden (Chair)

### Symptom burden in CKD patients on haemodialysis

Marianne Rix, Denmark

### Screening for symptoms: a pivotal role for nurses in the dialysis clinic

Jeanette Finderup, Denmark

### Understanding CKD-associated Pruritus and exploring its prevalence

Stefan Jacobson, Sweden (Chair)

### Sharing experience of a new era for the treatment of CKD-associated Pruritus


Markus Knittel, Germany

### Audience Q&A

All

### Summary and meeting close

Stefan Jacobson, Sweden (Chair)





KDIGO is delighted to invite you to attend our scientific symposium at ERA 2024.

## KDIGO update - The impact of viral infections in patients with renal diseases and the role of vaccination in kidney care



23 May 2024 | 12:15–13:15 CEST

in Room A5 (*in person and live-streamed*)

NX-GBL-HZU-ADVR-240001  
Date of preparation: April 2024

©2024 GSK group of companies or its licensor. All rights reserved.  
GlaxoSmithKline Biologicals SA, Rixensart, Belgium.



For Healthcare Professionals Only  
GSK product data will be discussed  
KDIGO scientific symposium developed with support from GSK at ERA 2024



### Viral encounters: Understanding the burden on kidney health

Prof. Uyen Huynh-Do, Switzerland



### Case study 1: Navigating risks for patients with CKD and GD

(Chair) Prof. Steven Chadban, Australia



### Case study 2: Overcoming barriers for patients on dialysis

Prof. Michel Jadoul, Belgium



### Case study 3: Addressing challenges for patients with kidney transplant

Prof. Deepali Kumar, Canada



### Panel discussion and Q&A

All faculty members

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44800 221 441.

# Carrying the torch:

## SGLT2 inhibitors as a standard of care for CKD

Thursday, May 23<sup>rd</sup> 2024; 12:15–13:15 CEST  
Room A6



**Mustafa  
Arıcı (Chair)**  
Turkey



**Kieran  
McCafferty**  
United Kingdom



**Beatriz  
Fernández-Fernández**  
Spain



**Xavier  
Cos**  
Spain

**Join our expert faculty as we focus discussions around:**

- The use of SGLT2 inhibitors as a standard of care for patients with CKD
- How to apply the latest guideline recommendations to optimize GDMT for the diverse range of patients with CKD encountered in clinical practice
- Recognizing the dual role of nephrologists within the multidisciplinary team in driving practice change and transforming kidney care

Throughout our discussion-led, interactive, multidisciplinary session agenda:

Time (CEST)	Agenda
12:15–12:20	<b>Welcome and introduction</b> Mustafa Arıcı
12:20–12:30	<b>Lighting the fire: SGLT2 inhibitors at the core of treatment for CKD</b> Beatriz Fernández-Fernández
12:30–12:40	<b>Leading the race: The dual role of the nephrologist</b> Kieran McCafferty, Xavier Cos, Beatriz Fernández-Fernández
12:40–13:00	<b>Going for gold: Optimizing care for your patients</b> Xavier Cos, Kieran McCafferty, Beatriz Fernández-Fernández
13:00–13:10	<b>Q&amp;A</b> All faculty
13:10–13:15	<b>Closing remarks</b> Mustafa Arıcı

This non-promotional symposium is organized and funded by AstraZeneca for healthcare professionals only  
Veeva ID: SE-16237, Date of Preparation: March 2024

CKD, chronic kidney disease; GDMT, guideline-directed medical therapy; SGLT2, sodium-glucose co-transporter 2

AstraZeneca



For Healthcare Professionals only

# Advancing lupus nephritis care

Acting early to preserve the kidney

24<sup>th</sup> May, 10:15–11:15 CEST

Room K1 + K2



Chair

**Professor Hans-Joachim Anders, Germany**



The evolution of lupus nephritis care: recommendations and guidelines

Achieving renal response in lupus nephritis

**Professor Onno Teng, The Netherlands**



Case practice session:




What is 'early' intervention in lupus nephritis?

**Professor Julia Weinmann-Menke, Germany**

A promotional industry symposium organised and funded by GSK. GSK products will be discussed.  
Prescribing Information for all GSK products discussed will be available at the event and the GSK booth.

GlaxoSmithKline AB. Phone: 08-6389300.

Join us  
at our industry  
symposium





Cardiovascular. Renal. Metabolic.

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*



## Slope of change in the right direction: overcoming residual risk for progression in CKD

Friday 24 May | 10:15–11:15 CEST | Room A2+A3

With: Adeera Levin | Merlin Thomas | Peter Rossing | Paola Fioretto

Join our expert speakers to discuss recent progress and future advances in the treatment of CKD, including how we can:

- Further reduce the risk of disease progression, considering CKD within the cardiovascular-renal-metabolic disease spectrum
- Collaborate with primary care to improve early diagnosis and support implementation of guideline-recommended therapies

Find us in the exhibition hall at stand B550



Scan to view the full programme

ERA hybrid congress 2024  
Stockholm, Sweden & virtual  
23–26 May 2024

# Time for change: A new era for C3G and primary IC-MPGN

**Friday, 24 May 2024**  
10:15–11:15 CEST  
**Room A4**



61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

A multidisciplinary expert panel featuring...

**Chair's welcome**  
Antonio Mastrangelo, Italy

**The path to diagnosis: patient journeys in C3G and primary IC-MPGN**  
Antonio Mastrangelo, Italy

**Behind the curtain: C3 in C3G and primary IC-MPGN**  
Elena Goicoechea de Jorge, Spain

**Looking to the future of treatment in C3G and primary IC-MPGN**  
Erica Daina, Italy


**Closing remarks and Q&A**  
All faculty  
Chair: Antonio Mastrangelo, Italy

EBAC Accredited Educational Programme during the 61<sup>st</sup> ERA congress

61<sup>st</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

# Chronic cardiovascular-kidney disorder – optimizing therapy through a multidisciplinary approach

**Friday, May 24, 2024, 10:15-11:15 CEST (UTC +2)**  
**A5 Room,** Stockholm, Sweden



Chairs: **Cecilia Linde**, Stockholm, Sweden, **Beatriz Fernández-Fernández**, Madrid, Spain

10:15–10:17

## Welcome and introduction

Cecilia Linde, Stockholm, Sweden

10:17–10:27

## Chronic cardiovascular-kidney disorder: the cardiorenal syndrome revisited

Carmine Zoccali, Reggio Calabria, Italy

10:27–10:37

## Foundational pharmacological therapy in patients with cardiovascular and kidney dysfunction

Gianluigi Savarese, Stockholm, Sweden

10:37–10:47

## Management of hyperkalaemia – how to maintain guideline-directed therapy in patients with kidney and heart disease?

Philip A. Kalra, Salford, UK

10:47–11:12

## Case-based interactive panel discussion

All faculty

11:12–11:15

## Concluding comments and EBAC evaluation

Beatriz Fernández-Fernández, Madrid, Spain

Please scan  
this QR code to  
complete the EBAC  
evaluation form



### Educational objectives

- Present the rationale for the conceptual framework of chronic cardiovascular-kidney disorder, highlighting common risk factors and pathophysiological mechanisms between cardiovascular and kidney dysfunction.
- Discuss the pathophysiological rationale and cardiorenal benefits of renin-angiotensin-aldosterone system (RAAS) modulation, beta-blockade, sodium-glucose co-transporter (SGLT) inhibition and diuretic therapy in patients with chronic kidney disease (CKD), heart failure (HF), and comorbidities such as resistant hypertension and type 2 diabetes.
- Emphasize the importance of a multidisciplinary approach in the management of patients with chronic cardiovascular-kidney disorder.
- Recognise the importance of hyperkalaemia as a barrier to optimal RAAS inhibitor therapy and highlight the need for close monitoring of serum potassium in patients treated with RAAS inhibitors.
- Evaluate the role of novel potassium binders in optimizing the use of RAAS inhibitor therapy in patients with CKD, HF and other risk factors for hyperkalaemia.



This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association physicians may convert EBAC® CE credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Organized by MedEd Global Solutions  
Supported by an unrestricted educational grant from CSL Vifor

# Comprehensive Approaches to CHRONIC KIDNEY DISEASE: IMPROVING DIAGNOSIS AND PATIENT MANAGEMENT

## LIVE SYMPOSIUM



FRIDAY, MAY 24<sup>TH</sup>

10:15 AM - 11:15 AM

LUNCH MEETING

### FEATURES

- Complimentary Office Posters
- Case Analysis Simulation Challenge

### VENUE

Stockholmsmässan  
Mässvägen 1 Älvsjö  
125 80 Stockholm

ROOM A6



### SPEAKERS



Roberto Pontremoli, MD, PhD

Full Professor  
Department of Internal Medicine  
Director, Internal Medicine Clinic  
Director, School of Emergency  
and Urgent Medicine  
San Martino Hospital of Genoa  
Institute of Scientific Hospitalization and Care  
Genoa, Italy



Christoph Wanner, MD, FERA

Professor of Medicine  
University of Würzburg  
Department of Clinical Research  
and Epidemiology  
Renal Research Unit  
Comprehensive Heart Failure Center  
(CHFC)  
Würzburg, Germany

### AGENDA

- I. Barriers to optimal CKD Management
- II. Diagnosis
- III. Therapeutic Interventions and Associated Clinical Trial Data
- IV. Multidisciplinary Care Approaches
- V. Case Studies
- VI. Open Discussion
- VII. Conclusion/Q&A

The ERA assumes no responsibility for the information published in this document.

This activity is provided by Med Learning Group.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim and Eli Lilly and Company.



61<sup>st</sup> ERA Congress Stockholm & Virtual

# Addressing the “IgA” in IgAN

Friday, May 24<sup>th</sup>: 10:15–11:15 AM  
Room A7



## Chair Prof. Bengt Fellström

Senior Professor at the Uppsala University Hospital in Sweden.

## Speakers

Dr. Claudia Seikrit,  
University Hospital Aachen, Germany

Dr. Michelle O'Shaughnessy,  
University Hospital Galway, Ireland

## Program

10:15–10:20

Welcome and Introduction

Prof. Bengt Fellström

10:20–10:40

From a Multi-Hit Hypothesis  
to Multi-Hit Treatment?

Dr. Claudia Seikrit

10:40–11:00

Navigating the IgAN Treatment Development  
Journey: Lessons Learned and Future Prospects

Dr. Michelle O'Shaughnessy

11:00–11:15

Discussion and Closing Remarks

IgAN: Immunoglobulin A Nephropathy

Come visit  
our booth.  
**C.520**

STADA Arzneimittel AG  
Stadastraße 2–18  
61118 Bad Vilbel  
Germany




# Our call to action:

A united approach  
to managing hyperkalaemia  
in patients with cardiorenal disease

**FRIDAY 24<sup>TH</sup> MAY 2024**

**10:15–11:15 CEST**

**ROOM T5**



**SCIENCE COLLECTED**

Sponsored by an unrestricted educational grant from AstraZeneca.



**James Burton (Chair)**  
University of Leicester,  
UK



**María Jesús Izquierdo Ortiz**  
Burgos University Hospital,  
Spain



**Aaron Wong**  
Princess of Wales Hospital,  
UK

By the end of this symposium, the audience should be able to:

- Understand the importance of choosing the right treatment pathway for patients with hyperkalaemia
- Identify steps to achieve optimal RAAS inhibitor therapy while managing hyperkalaemia
- Discuss the role of the multidisciplinary team for the management of hyperkalaemia in patients with cardiorenal disease

Throughout our discussion-led, interactive, multidisciplinary session agenda:

Time (CEST)	Agenda
10:15–10:20	Welcome and introductions James Burton
10:20–10:25	Our options: Why I choose potassium control over RAAS inhibitor therapy adjustment Aaron Wong
10:25–11:00	Hyperkalaemia rethought: Optimising guideline-directed medical therapy for cardiovascular-kidney-metabolic health Panel discussion James Burton, María Jesús Izquierdo Ortiz, Aaron Wong
11:00–11:10	Q&A All faculty
11:10–11:15	Closing remarks James Burton

SPONSORED SYMPOSIUM AT THE 61ST ERA CONGRESS

# Targeting the Source of IgA Nephropathy: Focus on BAFF and APRIL Pathways

Friday 24 May 2024 · 13:45–14:45pm CEST · Room K1+K2

CHAIR



**Chee Kay Cheung, MBChB, PhD**

Consultant Nephrologist & Honorary Associate Professor  
The Mayer IgA Nephropathy Laboratories, University of Leicester, UK  
John Walls Renal Unit, University Hospitals of Leicester, UK

FACULTY



**Heather Reich, MD CM, PhD, FRCPC**

Division Director of Nephrology  
University of Toronto, Canada



**Jürgen Floege, MD**

Senior Professor, Division of Nephrology and Rheumatology  
University of Aachen, Germany

AGENDA


**Overview of the Pathophysiology and  
Unmet Need in IgA Nephropathy**

**The Role of Cytokines, BAFF and APRIL,  
in the Pathogenesis of IgAN**

**Emerging Disease-modifying Therapies  
Targeting BAFF and APRIL**

Q&A

SUPPORTED BY  
**Vera**  
therapeutics



61<sup>st</sup> ERA Congress, Stockholm and virtual

## Is high-volume HDF the future standard of care in chronic dialysis?

### Industry Symposium

Friday, May 24<sup>th</sup> 13:45–14:45

Room: A2 + A3 and live stream

#### Chair:

Bernard Canaud, France

13:45–13:50 Introduction

Bernard Canaud, France

13:50–14:05 CONVINCE trial: Leveraging emerging evidence to support high-volume HDF

Peter Blankestijn, The Netherlands

14:05–14:20 CONVINCE in the context of the totality of evidence

Giovanni Strippoli, Italy

14:20–14:45 Panel discussion: Real-world clinical experience and practical consideration with implementing high-volume HDF including Q&A

All faculty and Rukshana Shroff, United Kingdom

For more information, please visit us at booth F.200

## Novartis-sponsored symposium on C3 Glomerulopathy

# ERA 2024

### Should disease control be redefined in C3G? Current evidence targeting the alternative complement pathway as the underlying cause of C3G

This symposium is organized and funded by Novartis Pharma AG and is intended for an audience of non-US HCPs within the context of the ERA Congress 2024, taking place in Stockholm, Sweden.

The ERA assumes no responsibility for the information published in this document.

Novartis Pharma AG  
© 2024 Novartis Pharma AG, CH-4002 Basel, Switzerland  
FUSEMLR ID: 423331 | March 2024

 NOVARTIS | Reimagining Medicine

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
Inspiring Kidney Care

### Welcome from the Chair

It is our great pleasure to welcome you to this Novartis-sponsored symposium, live at the 61<sup>st</sup> ERA Congress.

In today's program we will examine the pathophysiology and classification of C3 glomerulopathy (C3G), and highlight the diagnostic challenges currently faced by patients and HCPs. We will review the current disease management strategies in C3G, with a focus on disease control and treatment goals, alongside the potential impact of forthcoming treatment innovations to address the unmet medical needs in these patients.

We will explore these topics via engaging presentations, and we warmly encourage your active participation during the Q&A session. We hope you enjoy what we anticipate will be an interesting and informative session.

**Marina Vivarelli**

Laboratory of Nephrology and Clinical Trial Center, Bambino Gesù Pediatric Hospital and Research Center, Rome, Italy

### Should disease control be redefined in C3G? Current evidence targeting the alternative complement pathway as the underlying cause of C3G

**Friday, 24 May 2024 | 13:45–14:45 (CET)**

Room A4, Stockholmsmässan, Stockholm, Sweden

### Agenda

**5 min   Welcome and introduction**  
Chair: Marina Vivarelli, Italy

**20 min   Current challenges with diagnosis and redefining disease control in C3G**  
Edwin Wong, UK

**20 min   Insights on innovative treatment approaches for patients with C3G**  
Fadi Fakhouri, Switzerland

**13 min   Audience Q&A**  
All faculty (Moderated by the Chair)

**2 min   Closing remarks**  
Chair: Marina Vivarelli, Italy

### Faculty



**Marina Vivarelli (Chair)**

Laboratory of Nephrology and Clinical Trial Center, Bambino Gesù Pediatric Hospital and Research Center, Rome, Italy



**Edwin Wong**

National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK



**Fadi Fakhouri**

Centre Hospitalier Universitaire Vaudois Lausanne, and University of Lausanne, Lausanne, Switzerland

CME-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2024

# Elevating AAV Care: Expert Strategies for Optimal Patient Outcomes

Friday, May 24, 2024 | 13:45 - 14:45 CEST

Stockholmsmässan Mässvägen 1 Älvsjö, Room: A5

After attending this symposium, attendees will be able to:

- Identify the role of the alternative complement pathway in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- Evaluate the frequency of relapse and impact of medication-related toxicity associated with the use of traditional standard of care medications in the management of patients with AAV
- Develop patient-centered and evidence-based induction and maintenance treatment strategies to achieve sustained remission and mitigate treatment-associated toxicity in patients with AAV



**CHAIR:**  
Annette Bruchfeld, MD, PhD  
Professor of Nephrology  
Linköping University  
Guest Professor  
Karolinska Institutet  
Unit of Renal Medicine  
Stockholm, Sweden



**FACULTY:**  
Stephen McAdoo, MD  
Consultant Nephrologist  
Imperial College Healthcare  
NHS Trust  
London, United Kingdom



**FACULTY:**  
Andreas Kronbichler, MD  
Assistant Professor  
Medical University Innsbruck  
Innsbruck, Austria

The ERA assumes no responsibility for the information published in this document.  
This activity is supported by an independent educational grant from CSL Vifor.



20



## KDIGO 2024 GUIDELINE ON LUPUS NEPHRITIS (LN) A Roundtable Discussion

FRIDAY, MAY 24 | 13:45 – 14:45 CET  
ROOM A6 | ERA CONGRESS 2024  
STOCKHOLM, SWEDEN

### Chairs

BRAD ROVIN | USA

VLADIMIR TESAR | CZECHIA

### Living with Lupus – A Patient Perspective

JEANETTE ANDERSEN | DENMARK

### An Introduction to the KDIGO Guideline on LN – Update on Initial Therapy for Proliferative LN (Class III or IV)

JUAN MANUEL MEJIA-VILET | MEXICO

### An Introduction to the KDIGO Guideline on LN – Update on Maintenance Therapy for Proliferative LN (Class III or IV)

ISABELLE M. AYOUB | USA

Please join us for an AstraZeneca-sponsored symposium at the 61<sup>st</sup> ERA Congress

# Staying INFORMed: preparing for the future of SARS-CoV-2 in patients with chronic kidney disease



Friday 24 May 2024 | 13:45–14:45 CEST  
Room A7, Stockholmsmässan, Stockholm

Our panel of global experts will be drawing on their collective clinical experience and the very latest research to explore the continued importance of recognising and responding to COVID-19 risk in patients with chronic kidney disease. Come and be part of the conversation!

**13:45–13:50** Welcome and introduction



**Anders Sönnnerborg** MD, PhD

Chairperson  
Karolinska Institute,  
Stockholm, Sweden

22

**13:50–14:10** Leaving no one behind: recognising COVID-19 risk in patients with chronic kidney disease



**Mustafa Arici** MD, FERA  
Hacettepe University,  
Ankara, Turkey

**14:10–14:30** Strategies for protection: addressing COVID-19 risk in patients with chronic kidney disease



**Julia Weinmann-Menke** MD  
Johannes Gutenberg University  
Mainz, Mainz, Germany

**14:30–14:45** Panel discussion and Q&A

All



## Fabry First: Monitoring Matters

Friday 24 May, 2024 | Room: T5  
13:45–14:45 (CEST)



Welcome and introduction	<b>Chair: Alberto Ortiz</b> Fundación Jiménez Díaz, Madrid, Spain
Leveraging real-world evidence to improve patient care	<b>Alberto Ortiz</b> Fundación Jiménez Díaz, Madrid, Spain
Using biomarkers to define a personalized approach	<b>Albina Nowak</b> University Hospital Zurich, Switzerland
Demystifying anti-drug antibodies and neutralizing antibodies	<b>Alberto Ortiz</b> Fundación Jiménez Díaz, Madrid, Spain
Learnings from switching therapies - how to monitor and evaluate outcomes	<b>Federico Pieruzzi</b> Università degli Studi di Milano-Bicocca, Italy and <b>Aleš Linhart</b> Charles University in Prague, Czech Republic
Q&A and panel discussion	All

Please note: Product information will be discussed during this symposium.

Alberto Ortiz



Albina Nowak



Federico Pieruzzi



Aleš Linhart



Health Research Institute of the Jiménez Díaz Foundation, Madrid, Spain

University Hospital Zurich, Switzerland

Università degli Studi di Milano-Bicocca, Italy

Charles University in Prague, Czech Republic

We hope to see you there!

# Genetics for kidney diseases: from nephropathies diagnosis to transplant management

**Friday, 24 may 2024 | 18:15 - 19:15**

**PROGRAMME** **ROOM A4**

You can  
also meet us  
at our booth  
**#B.425**

Eurofins is a worldwide leader in clinical diagnostics. Speakers will demonstrate usefulness of genetic diagnosis in nephrologists' daily practice, with the latest advances on genetics testing, from nephropathies diagnosis with Exome Sequencing to transplant management with donor derived cell free DNA (dd-cDNA) and Gene Expression Profiles.



**Chair:** Dr Marine Dancer, Clinical pathologist, Lyon, France

**18:15 - 18:25** **Exome sequencing: all-in-one genetics for adult kidney diseases?**

Junior Dr Ilias Bensouna, Nephrology resident, Paris, France

**18:25 - 18:35** **Exome sequencing to improve characterization of hypertensive nephropathy (HN)**

Dr Justine Serre, Nephrologist, Paris, France

**18:35 - 18:45** **From rapid to fast nephrogenomics for adult's CKD and Thrombotic microangiopathies**

Dr Nadhir Yousfi, Molecular biology Research Engineer, Paris, France

**18:45 - 18:55** **Towards a non-invasive follow-up of transplanted patients**

Dr Pedro Ventura, Nephrologist, Barcelona, Spain

**18:55 - 19:15** **Q&A session**



Dr Marine Dancer



Junior Dr Ilias Bensouna



Dr Justine Serre



Dr Nadhir Yousfi



Dr Pedro Ventura

We cordially invite you to the Alexion, AstraZeneca Rare Disease Satellite Symposium  
at the 61<sup>st</sup> Annual Scientific Meeting of The European Renal Association

# Challenges in the personalised management of atypical haemolytic uraemic syndrome (aHUS)

**Friday 24 May 2024,  
18:15–19:15 (CET)**

Room A5, Stockholmsmässan  
Convention Center and Virtual

## Programme

**aHUS diagnosis and clinical practice**

**Treatment options for aHUS patient types**

**Patient-focused approaches to aHUS management**

**Q&A session**

**Closing remarks**

## Faculty

**Dr Jeffrey Laurence**  
New York, USA

**Dr Ana Ávila Bernabéu**  
Valencia, Spain

**Dr Jeffrey Laurence**  
New York, USA

All speakers  
All speakers

25

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024

This symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. Alexion, AstraZeneca Rare Disease products may be discussed at this event. This event is intended for healthcare professionals only. Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA.

The content of each presentation was prepared independently by the speaker, with limited feedback from Alexion, AstraZeneca Rare Disease.

The views expressed by the speakers are not made on behalf of Alexion, AstraZeneca Rare Disease and do not necessarily represent the position of the company.

The ERA assumes no responsibility for the information published in this document.

Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA 02210  
Alexion, AstraZeneca Rare Disease document number: M/INT/ULT-a/0056

**ALEXION®**  
AstraZeneca Rare Disease

March 2024

## HEMOADSORPTION IN CHRONIC HEMODIALYSIS



**Chair & Speaker:**  
Claudio Ronco,  
Italy



**Chair:**  
Mario Cozzolino,  
Italy



**Speaker:**  
Dimitrios Petras,  
Greece



**Speaker:**  
Eladio Peñaranda,  
Philippines

26

- Inflammation Mitigation Hypothesis
- Efficacy and Safety of Hemoabsorption in Dialysis Patients: The Greek Experience
- Makati Medical Center's Hemoabsorption Experience

Time: 18:15-19:15 CET

Date: Friday, May 24th

Location: Stockholmsmässan, Room A6



**AsahiKASEI**  
ASAHI KASEI MEDICAL



61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

## THERAPEUTIC APHERESIS: EFFICACY AT CELLULAR LEVELS

MAY 25<sup>TH</sup> 2024

Rooms K1+K2 - 10:15-11:15



### CHAIRMAN

Prof. Reinhard Klingel  
*Cologne, Germany*



**10:15**  
Dr. Tiziana  
Sampietro  
*Pisa, Italy*

**Extracorporeal removal of Lipoprotein(a)  
restores endothelial function.**



**10:35**  
Dr. Arnaud  
Lionet  
*Lille, France*

**Role of Rheopheresis in combination with  
hemodialysis in calciphylaxis management.**



**10:55**  
Prof. Jan T.  
Kielstein  
*Braunschweig,  
Germany*

**TPE in sepsis: is giving more blessed?**



SATURDAY, MAY 25, 2024  
10:15-11:15 CEST  
Hall A2+A3 / Virtual

SAVE THE DATE

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
Inspiring Kidney Care

# Clinical Markers in IgA Nephropathy: Is All Proteinuria the Same?



**Prof. Jonathan Barratt**  
Chair

College of Medicine,  
Biological Sciences  
and Psychology,  
University of Leicester,  
Leicester, UK



**Dr. Shikha Wadhwani**

Division of Nephrology  
and Hypertension,  
Northwestern University,  
Feinberg School of Medicine,  
Chicago, IL, USA



**Prof. Richard Lafayette**

Division of Nephrology,  
Department of Medicine,  
Stanford University,  
Stanford, CA, USA

## Agenda

10:15-10:25	<b>Welcome and Introduction</b> (Prof. Jonathan Barratt)
10:25-10:40	<b>Predicting Long Term Clinical Outcomes in IgA Nephropathy</b> (Dr. Shikha Wadhwani)
10:40-10:55	<b>What Can Be Learned from Recent Trials in IgA Nephropathy: A Shifting Approach</b> (Prof. Richard Lafayette)
10:55-11:15	<b>Panel Discussion and Q&amp;A</b> (All Faculty)

28



# Making a difference with SGLT2 inhibitors in cardiovascular, renal and metabolic conditions: what has clinical experience taught us?

SATURDAY 25 MAY 2024  
10:15–11:15 AM CEST  
Room A4

Rikke Borg, Alice Cheng,  
Adeera Levin and Erin Michos



# EVOLVING STRATEGIES IN THE MANAGEMENT OF ANEMIA IN CKD & ESRD-FOCUS ON HIF-PHIS

25<sup>th</sup> MAY 2024

10:15 to 11:15 AM



Room A5



## Optimal Anemia Management with Iron therapy in CKD



10:15 to 10:30 am

### Speaker



**Dr. Tarun Jeloka**  
Manipal Hospital,  
Pune, India

### Chairpersons



**Dr. Narayan Prasad**  
Sanjay Gandhi Institute of  
Medical Sciences, Lucknow,  
India



**Dr. Dibya Singh Shah**  
Tribhuvan University Teaching Hospital,  
Kathmandu, Nepal.

## Unlocking the potential of HIF-PHIs: The Novel Approach for Managing CKD Anemia



10:30 to 10:45 am

### Speaker



**Dr. Dinesh Khullar**  
Max Super Specialty Hospital- Saket,  
New Delhi, India

### Chairpersons



**Dr. D S Rana**  
Sir Ganga Ram Hospital,  
Delhi, India



**Dr. Manjuri Sharma**  
Guwahati Medical College,  
Guwahati, India

## Panel Discussion- Clinical Utility of HIF PHIs in the Indian Real-World Setting



10:45 to 11:15 am

### Moderator



**Dr. Sampath Kumar**  
Meenakshi Mission Hospital and  
Research Center, Madurai, India

### Panelists



**Dr. Manisha Sahay**  
Osmania Medical College &  
Hospital, Hyderabad, India



**Dr. Sanjeev Gulati**  
Fortis Group of Hospital,  
Delhi, India



**Dr. Shyam Bihari Bansal**  
Medanta- the Medcity,  
Gurugram, India.



**Dr. Pratik Das**  
RN Tagore Hospital,  
Kolkata, India

Welcome to the Astellas-sponsored symposium at ERA 2024

# Anaemia of CKD: towards long-term treatment success

Saturday 25 May 2024 | 10:15–11:15 CEST  
Room A6, Ground Floor, Stockholmsmässan

Time	Session	Speaker
10:15–10:20	Welcome and introductions	Professor Michel Jadoul (chairperson)
10:20–10:30	The evolving management of CKD	Associate Professor Marie Evans
10:30–11:00	HIF-PH inhibitors debate	Professor Roberto Minutolo Associate Professor Marie Evans
11:00–11:10	HIF-PH inhibitors in the real world: experiences with roxadustat in patients in Norway	Dr Joe Chan, PhD
11:10–11:15	Q&A and meeting close	All

This symposium has been sponsored by Astellas Pharma and is intended for healthcare professionals only.

This symposium includes content related to clinical experience with an Astellas nephrology product.

The ERA assumes no responsibility for the information published in this document.

Please note that indications and availability of products may vary between countries.

Refer to your local Summary of Product Characteristics/Prescribing Information for details.

CKD, chronic kidney disease; EMA, European Medicines Agency; ERA, European Renal Association; HIF-PH, hypoxia-inducible factor prolyl hydroxylase.

©2024 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.

MAT-SE-EVZ-2024-00003 | Date of preparation: April 2024 | Date of expiry: July 2024

Join our expert faculty as they explore recent advances in the management of CKD and implications for long-term patient outcomes, debate the use of HIF-PH inhibitors for adult patients with anaemia of CKD, and share their real-world clinical experience with roxadustat.



**Chairperson:**  
**Professor Michel Jadoul,**  
University Hospital  
Saint-Luc, UCLouvain,  
Brussels, Belgium



**Associate Professor**  
**Marie Evans,**  
Karolinska Institute,  
Stockholm, Sweden



**Professor**  
**Roberto Minutolo,**  
University of Campania  
Luigi Vanvitelli, Naples,  
Italy



**Dr Joe Chan, PhD,**  
Akershus University  
Hospital, Lørenskog,  
Norway

What if there is a way to individualize dialysis treatment to benefit patients?

Explore how a low-thrombogenic dialyzer reduces anti-coagulation exposure to elevate patients' quality of life.

## SAVE THE DATE

Join the industry symposium organized by Nipro during the 61<sup>st</sup> ERA congress

Get ready to redefine your approach to dialysis care!

**Individualization in Dialysis : Elevating quality of life**  
New practical approach or just wishful thinking?

The ERA assumes no responsibility for the information published in this document



25<sup>TH</sup> MAY

10:15 – 11:15

ROOM - A7

Stockholmsmässen,  
Mässvägen 1 Älvsjö,  
125 80 Stockholm,  
Sweden

**NIPRO**  
Live Longer. Live Better.

[www.nipro-group.com](http://www.nipro-group.com)

Breakfast will be provided.

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024



Prof. Meijers (Leuven University Hospital, Belgium)  
Chairman

### Enhancing Dialysis Outcomes Strategies for Improved Patient Survival



Prof. de Sequera (Infanta Leonor University Hospital, Spain)

### The Importance of an Optimized Anticoagulation Strategy Impact on Dialyzer Thrombogenicity and Patient's Quality of Life



Prof. Elot (Ghent University Hospital, Belgium)

61<sup>st</sup> European Renal Association (ERA) Congress

## What's new in Lupus Nephritis: from guidelines to real-world practices

A promotional symposium organised and funded by Otsuka Pharmaceutical Europe Ltd, intended for Healthcare Professionals only

Saturday 25<sup>th</sup> May 2024

10.15–11.15 (CET)

Room T5  
Stockholmsmässan  
(Virtual option will be available)

**Chair**

**Professor Onno Teng** Nephrology Clinician-Scientist  
Department of Internal Medicine Leiden University Medical Center, Netherlands

**Speakers**

**Professor Margherita Zen** Rheumatologist and Associate Professor Department of Medicine University of Padua, Italy

**Professor Annette Bruchfeld** Professor of Renal Medicine Linköping University, Rheumatology Consultant, Linköping University Hospital, Sweden

**Overview**

The field of lupus nephritis (LN) is entering an exciting era, with a greater understanding of the disease and the availability of new therapeutic options providing the opportunity to further improve the clinical care of our patients. In this symposium, we will discuss some of the current hot topics in LN, consider the role of recently approved LN treatments, and share real-world experiences with these therapies through case-based discussion.

**Programme**

10.15–10.20	Introduction
10.20–10.30	Part 1 – Hot topics in Lupus Nephritis
10.30–10.40	Part 2 – Key recent clinical trials and guidelines in Lupus Nephritis
10.40–10.50	Part 3 – 2 years of experience in Lupus Nephritis with latest therapies in real-world setting
10.50–11.05	Part 4 – Interactive session – 2 clinical cases
11.05–11.15	Q&A

**Introducing the faculty**

**Professor  
Onno Teng**

Dr. Y.K.O. (Onno) Teng, MD, PhD is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC). He is head of the Nephrology outpatient clinic and coordinator of the Leiden outpatient clinic for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs) which accommodates top-referral, multidisciplinary, tertiary care on a regional and national level. He also leads and coordinates a clinical, multidisciplinary pathway aimed at counselling and guiding a pregnancy wish of patients with systemic lupus erythematosus (SLE) or antiphospholipid syndrome. He conducts a translational research program in the area of autoimmune glomerulonephritis related to SLE and ANCA-associated vasculitis (AAV).



**Professor  
Margherita Zen**

Professor Margherita Zen is a Rheumatologist and an Associate Professor within the Department of Medicine at the University of Padua, Italy.

Instructing courses in Clinical Rheumatology and Management of patients with systemic Autoimmune Rheumatic and Autoinflammatory diseases. Her research interests primarily focus on SLE and notably include studies on remission, low disease activity, and the use of biologics in SLE.



**Professor  
Annette Bruchfeld**

Professor Annette Bruchfeld is Professor of Renal Medicine at Linköping University and Consultant at Linköping University Hospital.

Her main research interests involve inflammatory kidney diseases, such as IgA nephropathy, and a more unusual group of autoimmune kidney diseases called ANCA-associated vasculitis. The aim of the research is to identify new biomarkers to help improve diagnosis, prognosis and monitoring. She is also involved in research on new treatment for kidney diseases, including more effective drugs with fewer side-effects aimed at kidney inflammation. The goal is to replace the more toxic immunosuppressant therapies used today and thereby reduce the burden of both the diseases and the treatment. During the COVID-19 pandemic, Annette Bruchfeld has been involved both as a researcher and a clinician in studying the vulnerability of people with kidney disease and advocating their priority for vaccination.



Anders Kristensson  
Type 2 diabetes  
Sweden

Dear colleagues,

On behalf of Novo Nordisk, we would like to invite you to our Industry Symposium at 61<sup>st</sup> ERA Congress 2024 entitled "**GLP-1 RAs: new possibilities for managing CKD in people with obesity and type 2 diabetes**" which will be held on **25<sup>th</sup> May, 13:45-14:45 CEST at Stockholmsmässan, Stockholm, Sweden**.

In this symposium, a world-renowned faculty, Peter Rossing (Denmark), Per-Henrik Groop (Finland), Katherine Tuttle (US) and Johannes Mann (Germany) will highlight the unmet medical needs for people with obesity/T2D and CKD, despite availability of current standard of care.

Focusing on obesity and T2D, the session will raise awareness around interconnectedness between CKD and other metabolic disorders. The experts will also discuss how GLP-1 RAs are increasingly being recognized for their potential for the treatment of CKD in people with obesity/T2D and CKD.

The symposium will consist of a mix of short presentations, panel discussion and Q&A, during which the attendees will have the opportunity to ask questions and engage with the expert speakers.

To take part in this symposium and the congress, you should register [here](#).

Additionally, visit us at [Science hub](#) for more information and ongoing updates.

We look forward to what promises to be a stimulating and educational symposium.

Kind regards,

**Marco Bo Hansen**

**Marco Bo Hansen, MD, PhD**  
Global Medical Director

Novo Nordisk symposium at 61<sup>st</sup> European Renal Association (ERA) Congress 2024

## GLP-1 RAs: new possibilities for managing CKD in people with obesity and type 2 diabetes

Saturday 25<sup>th</sup> May 2024, 13:45 – 14:45 CEST

Room K1+K2, Stockholmsmässan, Stockholm, Sweden and Online

03 mins **Welcome and Introduction**

*Chair: Peter Rossing (DK)*

10 mins **Role of GLP-1 RAs in the management of obesity and type 2 diabetes in people with CKD**

*Per-Henrik Groop (FIN)*

20 mins **New opportunities for the treatment of CKD in people with obesity and type 2 diabetes**

**(10 mins + 10 mins)**

*Katherine Tuttle (US) & Johannes Mann (DE)*

15 mins **Panel Discussion**

*All speakers*

10 mins **Audience Q&A**

*All speakers*

02 mins **Closing Remarks**

*Peter Rossing (DK)*



**Peter Rossing**  
Steno Diabetes Center,  
Copenhagen, Denmark



**Per-Henrik Groop**  
University of Helsinki,  
Helsinki, Finland



**Katherine Tuttle**  
University of Washington,  
Washington, US



**Johannes Mann**  
University of Erlangen-Nürnberg,  
Erlangen, Germany

34



CME-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2024

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

# Advancing IgAN Care:

## Expert Strategies for Transformative Patient Outcomes

Saturday, May 25, 2024 | 13:45 - 14:45 CEST

Stockholmsmässan Mässvägen 1 Älvsjö, Room: A2 + A3

After attending this symposium, attendees will be able to:

- Evaluate the benefits and limitations of the current standard of care for patients with IgA nephropathy (IgAN)
- Analyze data from recent and ongoing IgAN clinical trials
- Develop individualized treatment strategies to optimize outcomes in patients with IgAN



**CO-CHAIR:**  
Jürgen Floege, MD  
Senior Professor  
RWTH Aachen University Hospital  
Aachen, Germany



**CO-CHAIR:**  
Uyen Huynh-Do, MD  
Associate Professor  
Division of Nephrology & Hypertension  
Inselspital, University Hospital Bern  
Bern, Switzerland



**FACULTY:**  
Khalil El Karoui, MD, PhD  
Professor of Nephrology  
Tenon Hospital  
Sorbonne University  
Paris, France

The ERA assumes no responsibility for the information published in this document.  
This activity is supported by an independent educational grant from CSL Vifor.



35

A Medscape **LIVE!** EVENT

# A New Era in Transforming Kidney Health

## A Case-Based Showdown Between Audience and Experts

**SATURDAY, 25 MAY 2024 | 13:45 – 14:45 CEST | HYBRID 🎥**

**LUNCH:** 13:30 CEST | **PRESENTATION:** 13:45 CEST

STOCKHOLMSMÄSSAN, MÄSSVÄGEN 1 ÄLVSJÖ

STOCKHOLM, SWEDEN | **ROOM:** A4

### MODERATOR



**Navdeep Tangri, MD, PhD**  
Professor of Medicine  
University of Manitoba  
Winnipeg, Manitoba, Canada



**María José Soler, MD, PhD**  
Head of Nephrology and Clinical Dialysis Unit  
Nephrologist  
University Hospital Vall d'Hebron  
Barcelona, Spain

### PANELISTS



**Roberto Pecoits-Filho, MD, PhD**  
Professor of Medicine  
Pontifical Catholic University of Parana  
Curitiba, Brazil  
Scientific Director  
Arbor Research Collaborative for Health  
Ann Arbor, Michigan, United States



**David C. Wheeler, MD**  
Professor of Kidney Medicine  
University College London  
London, United Kingdom

Supported by an independent educational grant from AstraZeneca.


**Medscape**  
EDUCATION GLOBAL

61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024  
*Inspiring Kidney Care*

IME

## Novartis-sponsored Symposium on IgA Nephropathy

# ERA 2024



## A New Era for Managing IgA Nephropathy: Evolution of Clinical Approaches

This symposium is organized and funded by Novartis Pharma AG and is intended for an audience of non-US HCPs within the context of the ERA Congress 2024, taking place in Stockholm, Sweden.

The ERA assumes no responsibility for the information published in this document.

Novartis Pharma AG  
© 2024 Novartis Pharma AG, CH-4002 Basel, Switzerland  
FUSEMLR ID: 423341 | March 2024

 NOVARTIS | Reimagining Medicine

### Welcome from the Chair

I am delighted to welcome you to the Novartis-sponsored symposium on IgA nephropathy. We will discuss advances in the understanding of disease pathogenesis and the need for effective, targeted therapies. We will further explore how emerging therapeutic strategies could address current unmet needs and provide opportunities for the management of IgA nephropathy in future. Prior to the panel discussion, there will be a video presentation showing a patient's perspective on living with IgA nephropathy. We welcome your active participation during the Q&A session and hope you enjoy what will be an interesting and informative meeting.

**Heather Reich**

Baxter-Oreopoulos Division, Director of Nephrology, University of Toronto, Ontario, Canada

### A New Era for Managing IgA Nephropathy: Evolution of Clinical Approaches

**Saturday, 25 May 2024 | 13:45–14:45 (CEST)**

Room A5, Stockholmsmässan, Stockholm, Sweden

### Agenda

#### 5 min    Welcome and Introduction

Chair: Heather Reich, Canada

#### 15 min    IgA Nephropathy—clinical review and current challenges

Jonathan Barratt, UK

#### 15 min    What's next: novel treatment strategies with advancements in understanding of IgA Nephropathy

Hiddo Lambers Heerspink, The Netherlands

#### 20 min    Patient video followed by panel discussion and Q&A

All faculty (Moderated by the Chair)

#### 5 min    Closing Remarks

Chair: Heather Reich, Canada

### Faculty



**Heather Reich (Chair)**

Baxter-Oreopoulos Division  
Director of Nephrology,  
University of Toronto, Ontario, Canada



**Hiddo Lambers Heerspink**

Professor, Department of Clinical Pharmacy  
and Pharmacology, University Medical  
Center Groningen, The Netherlands



**Jonathan Barratt**

The Mayer Professor of Renal Medicine  
& Honorary Consultant Nephrologist,  
University of Leicester, Leicester, UK



Industry Symposium sponsored by Bayer on the occasion of the 61<sup>st</sup> ERA congress

# Finerenone in practice: Bridging evidence and guidelines with clinical use

Saturday 25 May, 13:45–14:45 CEST | Location: Symposia Room No. A6



**Maria Eriksson  
Svensson**  
(Chair, Sweden)



**David Cherney**  
(Canada)



**Csaba Kovesdy**  
(United States of America)



**Pantelis Sarafidis**  
(Greece)

Time	Title	Speaker
13:45–13:50	Welcome and introduction	Maria Eriksson Svensson
13:50–14:05	Advances in heart and kidney disease treatment: New insights into nonsteroidal MRAs	David Cherney
14:05–14:20	Finerenone in clinical practice: How can RWE support clinical decisions?	Csaba Kovesdy
14:20–14:35	State-of-the-art therapies for CKD in T2D	Pantelis Sarafidis
14:35–14:42	Q&A	All faculty
14:42–14:45	Summary and close	Maria Eriksson Svensson

**Prescribing Information:** Kerendia (finerenone) is a nonsteroidal, selective mineralocorticoid receptor antagonist. ATC code C03DA05, tablets 10 mg, 20 mg Rx (F). **Indication:** Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. For study results regarding renal and cardiovascular events, see section 5.1 of the SPC. **Subsidized only for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.** Contraindications: hypersensitivity to the active substance or to any excipient. Concomitant treatment with strong inhibitors of CYP3A4. Addison's disease. Warnings and precautions: Hyperkalemia has been observed in patients treated with finerenone. Some patients are at higher risk of developing hyperkalemia. Risk factors include low eGFR, high serum potassium, and previous episodes of hyperkalemia. In these patients, more frequent controls should be considered. If serum potassium is > 5.0 mmol/l, treatment with finerenone should not be initiated. If serum potassium is > 4.8 to 5.0 mmol/l, initiation of treatment with finerenone may be considered with additional monitoring of serum potassium during the first 4 weeks based on patient characteristics and serum potassium levels. If serum potassium is > 5.5 mmol/l, treatment with finerenone must be discontinued. The risk of hyperkalemia may also increase with concomitant use of drugs that may increase serum potassium levels. Treatment with finerenone should not be initiated in patients with severely impaired liver function, or in severely impaired renal function (eGFR < 25 ml/min/1.73 m<sup>2</sup>). Use during pregnancy and breastfeeding should not take place. Date of last revision of the Summary of Product Characteristics February 2023. Bayer AB. Box 606.169 26 Solna. Tel. 08-580 223 00. For further information, price and before prescribing, please read the product summary at [www.fass.se](http://www.fass.se)

■ This medicine is subject to extended monitoring. Healthcare professionals are encouraged to report any suspected side effects to the Swedish Medicines Agency

# NEPHROLOGISTS AS DECISION-MAKERS

A holistic approach for **pioneering care**  
in Rare Genetic Disorders



**THE 61<sup>ST</sup> ERA CONGRESS, SATURDAY MAY 25, 2024, 13:45 – 14:45**

Room A7, Stockholm & Virtual

Join our panel of experts at Chiesi's industry symposium as they discuss the pivotal role of nephrologists in clinical decision-making, particularly in the context of rare, multi-systemic, genetic disorders. We will assess the challenges and opportunities in the management of both nephropathic cystinosis and Fabry disease, presenting recent data in Fabry disease which may drive improved patient management.

We look forward to seeing you there.

## SESSION

Opening & Speaker Introduction

Elevating Holistic Care for Enhanced Cystinosis Management  
*Interactive Q&A with audience*

Managing Fabry Disease Today: Challenges and New Horizons  
*Interactive Q&A with audience*

Unlocking the Role of Anti-Drug Antibodies (ADAs) in Fabry Disease Treatment  
*Interactive Q&A with audience*

Closing Remarks

## FACULTY

Christoph Wanner, Würzburg, Germany

Aude Servais, Paris, France  
Elena Levchenko, Amsterdam, Netherlands

Bojan Vujkovac, Slovenj Gradec, Slovenia

João Gonçalves, Lisbon, Portugal

Christoph Wanner, Würzburg, Germany

This session is organized by Chiesi Farmaceutici S.p.A. and is for healthcare professionals only. This is not a continuing education (CE) activity.

Approval code: ALL\_24\_438 - 7599\_02.04.2024.

Date of preparation: March 2024

This symposium is for Healthcare Professionals and is organised and funded by MEDICE Arzneimittel Pütter GmbH & Co. The ERA assumes no responsibility for the information published in this document.

# The changing landscape of anaemia management in dialysis patients

25<sup>th</sup> May 2024, 13:45 – 14:45  
Room T5, Stockholm Fair

## AGENDA

**Chair: Professor Francesco Locatelli**

13:45 – 13:50

### Welcome and introduction

Professor Francesco Locatelli

Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy

13:50 – 14:05

### Current landscape of HIF-PHIs:

To seek to differentiate their clinical use in dialysis patients

Dr. Lucia Del Vecchio

Department of Nephrology and Dialysis,

Sant' Anna Hospital, ASST Lariana, Como, Italy

14:05 – 14:20

### Hidden struggles from the patient's perspective:

The psychological and practical challenges of anaemia management

Ms Jemma Reast, Expert Patient and Healthcare Insights Specialist, UK

14:20 – 14:40

### The ideal patient for vadadustat ▼: An interactive talk

Professor Sunil Bhandari, Consultant Nephrologist,

Hull University Hospitals NHS Trust, UK

14:40 – 14:45

### Closing remarks

Professor Francesco Locatelli



Please scan QR Code  
to view the Prescribing  
Information